194 related articles for article (PubMed ID: 36676678)
1. Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study.
Ibrahem HY; Aly DH; Warda AEA; Farahat RA; Youssef RM; Abdelhamid MH; Goud HA; Mohamed RR; Eldien MAYN; Alotaibi FO; Alzarea AI; Alanazi AS; Eisa NM; Refaee AS
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676678
[No Abstract] [Full Text] [Related]
2. Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study.
Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Badreldin HA; Alsalloum MA; Eljaaly K; Alharbi A; Aljehani R; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Al Aamer K; Al Enazi H; Almusallam M; Alshehri A; Bukhari R; Alasmari G; AlQahtani MM; Al Shammari S; Alsulaymi HO; Al Sulaiman K
J Intensive Care Med; 2023 Jun; 38(6):534-543. PubMed ID: 36683420
[No Abstract] [Full Text] [Related]
3. The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study.
Korayem GB; Aljuhani O; Altebainawi AF; Shaya AIA; Alnajjar LI; Alissa A; Aldhaeefi M; Kensara R; Al Muqati H; Alhuwahmel A; Alhuthaili O; Vishwakarma R; Aldardeer N; Eljaaly K; Alharbi A; Harbi SA; Katheri AA; Bekairy AMA; Aljedai A; Al Sulaiman K
Int J Infect Dis; 2022 Sep; 122():252-259. PubMed ID: 35605948
[TBL] [Abstract][Full Text] [Related]
4. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.
Sarhan RM; Madney YM; Abou Warda AE; Boshra MS
Int J Clin Pract; 2021 Jun; 75(6):e14079. PubMed ID: 33550688
[TBL] [Abstract][Full Text] [Related]
6. Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda.
El Rhalete A; Rhazi I; Bensaid A; Diass S; Kaouini A; Ounci E; Abdi M; Maarad M; Babouh C; Alami Z; Abda N; Bkiyer H; Housni B
Ann Med Surg (Lond); 2021 Jul; 67():102514. PubMed ID: 34221397
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab therapy for severely-ill COVID-19 pneumonia patients: a single-centre retrospective study.
Iqtadar S; Khan A; Mumtaz SU; Pascual-Figal DA; Livingstone S; Abaidullah S
J Physiol Pharmacol; 2022 Aug; 73(4):. PubMed ID: 36696245
[TBL] [Abstract][Full Text] [Related]
8. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients.
de Cáceres C; Martínez R; Bachiller P; Marín L; García JM
Pharmacol Rep; 2020 Dec; 72(6):1529-1537. PubMed ID: 33165762
[TBL] [Abstract][Full Text] [Related]
9. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Memon D; Kodre A; Potdar P; Mane M; Borse R; Pawar V; Patil D; Banerjee D; Bhoite K; Pharande R; Kalyani S; Raut P; Bapte M; Mehta A; Reddy MS; Bhayani K; Laxmi SS; Vishnu PD; Srivastava S; Khandelwal S; More S; Shinde R; Pawar M; Harshe A; Kadam S; Mahajan U; Joshi G; Mane D
Medicine (Baltimore); 2021 Jul; 100(29):e26705. PubMed ID: 34398044
[TBL] [Abstract][Full Text] [Related]
11. Observational study on off-label use of tocilizumab in patients with severe COVID-19.
Albertini L; Soletchnik M; Razurel A; Cohen J; Bidegain F; Fauvelle F; Safrano G; Piquet J; Maurer C; Goldgran-Toledano D
Eur J Hosp Pharm; 2021 Jan; 28(1):22-27. PubMed ID: 32912961
[TBL] [Abstract][Full Text] [Related]
12. The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.
Rubio-Rivas M; Mora-Luján JM; Montero A; Aguilar García JA; Méndez Bailón M; Fernández Cruz A; Oriol I; Teigell-Muñoz FJ; Dendariena Borque B; De la Peña Fernández A; Fernández González R; Gil Sánchez R; Fernández Fernández J; Catalán M; Cortés-Rodríguez B; Mella Pérez C; Montero Rivas L; Suárez Fuentetaja R; Ternero Vega JE; Ena J; Martin-Urda Díez-Canseco A; Pérez García C; Varona JF; Casas-Rojo JM; Millán Núñez-Cortés J;
J Gen Intern Med; 2022 Jan; 37(1):168-175. PubMed ID: 34664188
[TBL] [Abstract][Full Text] [Related]
13. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study.
Broman N; Feuth T; Vuorinen T; Valtonen M; Hohenthal U; Löyttyniemi E; Hirvioja T; Jalava-Karvinen P; Marttila H; Nordberg M; Oksi J
Clin Microbiol Infect; 2022 Jun; 28(6):844-851. PubMed ID: 35259529
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes.
Al-Baadani A; Eltayeb N; Alsufyani E; Albahrani S; Basheri S; Albayat H; Batubara E; Ballool S; Al Assiri A; Faqihi F; Musa AB; Robert AA; Alsherbeeni N; Elzein F
J Infect Public Health; 2021 Aug; 14(8):1021-1027. PubMed ID: 34153727
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.
Calderón-Ochoa C; Plamenov-Donchev N; Hernández-Quiñones F; Mendoza-López O; Hinojos-Gallardo LC; Longino-Gómez AJ; Hernádez-Saldaña R; Duque-Rodríguez J; Ishida-Gutiérrez MC
Microbiol Spectr; 2024 Jun; 12(6):e0249823. PubMed ID: 38687065
[TBL] [Abstract][Full Text] [Related]
16. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
[TBL] [Abstract][Full Text] [Related]
17. Is Tocilizumab An Effective Therapy For Severe Covid-19: A Single Center Study.
Sarfaraz S; Shaikh Q; Iftikhar S; Herekar FF; Saleem SG; Kanani F
J Ayub Med Coll Abbottabad; 2022; 34(4):747-754. PubMed ID: 36566393
[TBL] [Abstract][Full Text] [Related]
18. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Tocilizumab in COVID-19: Single-Center Experience.
Kaya S; Kavak S
Biomed Res Int; 2021; 2021():1934685. PubMed ID: 34977235
[TBL] [Abstract][Full Text] [Related]
20. Appropriate use of tocilizumab in COVID-19 infection.
Keske Ş; Tekin S; Sait B; İrkören P; Kapmaz M; Çimen C; Uğur S; Çelebi İ; Bakır VO; Palaoğlu E; Şentürk E; Çağlayan B; Çakar N; Tabak L; Ergönül Ö
Int J Infect Dis; 2020 Oct; 99():338-343. PubMed ID: 32726724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
